Liquid metformin: a gentler option for diabetes?
NCT ID NCT07300046
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will test whether a liquid form of metformin causes fewer stomach problems than the standard tablet. Twenty-four healthy adults will each try both the liquid and tablet versions in a random order. The goal is to see which is better tolerated, which could eventually help people with diabetes who have trouble with metformin pills.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- metformin
- What this could lead to
- If liquid metformin is better tolerated, it could offer an easier-to-take option for people who struggle with metformin tablets.
- What could go wrong
- This is a very early, small study in healthy volunteers, not people with diabetes. Results may not apply to patients, and the liquid form might not actually reduce side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female adults 18 to 55 years of age, inclusive. Body mass index (BMI) between 18.0 and 30.0 kg/m², inclusive. Medically healthy based on medical history, physical examination, vital signs, clinical laboratory evaluations, and 12-lead ECG, in the opinion of the investigator. Non-smoker or light smoker (10 cigarettes per day or fewer, or equivalent) willing to abstain during study confinement periods. Able to provide written informed consent before any study-specific procedures are conducted. Willing and able to comply with all study requirements, including fasting, dosing restrictions, and safety/tolerability assessments. Females of childbearing potential must use acceptable contraception as determined by the investigator. Exclusion Criteria: * Known hypersensitivity or contraindication to metformin or any excipients in the study formulations. History or presence of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or psychiatric disease that, in the investigator's opinion, could interfere with participation or data interpretation. Estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m², or any clinically significant abnormal clinical laboratory findings. Prior history of lactic acidosis. Current or recent (within 14 days before first dose) use of prescription drugs, over-the-counter medications, herbal products, or dietary supplements, unless approved by the investigator. Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV. Positive urine drug screen or positive alcohol breath test at screening or at check-in. Participation in another clinical trial or receipt of an investigational drug or device within 30 days or 5 half-lives (whichever is longer) before first study dose. Donation of ≥450 mL of blood, or significant blood loss, within 8 weeks before the first study dose. Pregnant or breastfeeding females. Women of childbearing potential not using acceptable contraception. Any condition or finding that, in the opinion of the investigator, would make the subject unsuitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe the nerve highways behind strength gains
- New syphilis test kits put to the test with donated blood
- Can a copy of a blockbuster arthritis drug match the original? scientists test it in healthy people
- Novo nordisk tests Brand-New molecule in humans for the first time
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?